600812 华北制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.1573.3582.3730.092-12.107
总资产报酬率 ROA (%)0.3000.8540.5990.023-2.987
投入资产回报率 ROIC (%)0.3701.0460.7260.028-3.593

边际利润分析
销售毛利率 (%)27.04331.00531.96631.98133.380
营业利润率 (%)2.9483.8303.1581.546-5.406
息税前利润/营业总收入 (%)6.8207.6127.4536.238-0.129
净利润/营业总收入 (%)2.1542.7862.1780.488-6.465

收益指标分析
经营活动净收益/利润总额(%)64.86179.54686.30948.541-33.271
价值变动净收益/利润总额(%)25.52416.96214.90029.552-7.790
营业外收支净额/利润总额(%)-0.3720.962-0.5971.314-0.453

偿债能力分析
流动比率 (X)0.7600.6560.7530.7810.724
速动比率 (X)0.5240.4610.5240.5270.521
资产负债率 (%)67.49567.81568.91470.07970.650
带息债务/全部投入资本 (%)66.49766.94967.26067.43867.070
股东权益/带息债务 (%)48.51947.38245.49845.40745.222
股东权益/负债合计 (%)38.69738.01536.42336.19235.352
利息保障倍数 (X)1.7562.0331.7281.335-0.024

营运能力分析
应收账款周转天数 (天)105.81686.88272.59274.02671.826
存货周转天数 (天)142.753138.929137.207134.173126.481